Abstract
In this article the statements “IB is involved with the patient charities Congenital Hyperinsulinism Charity, UK, and Congenital Hyperinsulinism International. PS is the founder of Congenital Hyperinsulinism India Association (CHIA), and is involved with the patient charities Congenital Hyperinsulinism Charity, UK (as Patron), and Congenital Hyperinsulinism International” in the Conflict of Interest section were incorrect but should have been “IB is involved with the patient charities Children’s Hyperinsulinism Charity, UK, and Congenital Hyperinsulinism International. PS is the founder of Congenital Hyperinsulinism India Association (CHIA), and is involved with the patient charities Children’s Hyperinsulinism Charity, UK (as Patron), and Congenital Hyperinsulinism International.” The original article has been corrected.
| Original language | English |
|---|---|
| Pages (from-to) | 101 |
| Number of pages | 1 |
| Journal | Paediatric Drugs |
| Volume | 28 |
| Issue number | 1 |
| DOIs |
|
| Publication status | Published - Jan 2026 |
Fingerprint
Dive into the research topics of 'Advances in Pharmacotherapy for Congenital Hyperinsulinism (nov, 10.1007/s40272-025-00727-0, 2025): Advances in Pharmacotherapy for Congenital Hyperinsulinism(Pediatric Drugs, 10.1007/s40272-025-00727-0)'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver